A combination of the drugs Kalydeco (ivacaftor) and lumacaftor successfully treated the defective CF protein, improved lung function, and helped reduce pulmonary exacerbations by 40%.
Spyryx Biosciences, Inc, has raised $18 million in financing, which will be used to develop therapies to treat respiratory conditions including cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD).
Vertex's investigational drug Orkambi (lumacaftor/ivacaftor) could potentially treat 8,500 Americans with cystic fibrosis aged 12 and older with two copies of the F508del mutation.
The Food and Drug Administration (FDA) is questioning whether an experimental combination therapy for cystic fibrosis (CF) from Vertex Pharmaceuticals has any added benefits over Kalydeco.
The European Commission has granted orphan medicinal product designation to AIT-CF, a cystic fibrosis treatment from Advanced Inhalation Therapies Ltd.
Corbus, a small biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab.
Nick Talbot, a 39-year-old man with cystic fibrosis, will attempt to be the first person with this condition to climb Mount Everest.
Cystic Fibrosis Foundation Therapeutics has provided a $14M grant to Genzyme to develop therapy options for cystic fibrosis patients with the common mutation F508del.
In a recent clinical study, use of AffloVest, a portable High Frequency Chest Wall Oscillation (HFCWO) vest, showed lung function improvements in a group of teens with cystic fibrosis.
New research from Prime Therapeutics indicates that new treatments for cystic fibrosis targeting gene mutations will notably increase health care costs.
A recent report on future trends in cystic fibrosis (CF) predicts a nearly 80% increase in the number of CF patients living into adulthood by the year 2025.
A New Mexico student collaborated with a laboratory at MIT to develop an automated cough monitor that aims to alert parents of children afflicted with cystic fibrosis to a coughing spasm.
New research from the Washington University School of Medicine reveals insight into possibly counteracting inappropriate mucus production in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than privately insured Americans.
Sollpura (liprotamase) is an investigational enzyme therapy appropriated for those with lower levels of digestive enzyme, or Exocrine Pancreatic Insufficiency (EPI) caused by several diseases, including cystic fibrosis.
The US FDA has expanded the approved use of Kalydeco for children aged two to five years with cystic fibrosis who have one of 10 mutations in their CFTR gene.
Using stem cells derived from skins of cystic fibrosis patients, scientists have generated organoid models of the distal part of lung tissue that may help them understand more about the disease.
In a first-of-its-kind study published in the ERJ, researchers have provided forecasts for the number of adults living with cystic fibrosis in 34 different European countries by the year 2025.
A team of researchers have found why mucus in the lungs of cystic fibrosis patients thickens, which makes them more vulnerable to lung infection.
UNC researchers have identified genetic pathways that play major roles in the severity of cystic fibrosis.